Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Drug-eluting stents begin to offer long-term financial benefits

Kalorama Information : 29 April, 2008  (Company News)
A new report published by Kalorama Information entitled ‘Major World Markets for Stents Major World Markets for Stents and the Economics of Drug-Eluting Technology, estimates that the current market for coronary stents in the seven major world healthcare markets is $4.9 billion.
Each year in the USA alone, almost 1 million people with coronary artery disease are treated with a percutaneous coronary procedure (PCI); worldwide the number is about 2.1 million.

Up to 50 percent will experience restenosis – the re-narrowing of the coronary artery – within three to six months. To prevent this, stents are delivered into the artery during about 70 percent of PCI procedures.

Recently, stents have been developed that are covered with drugs being released over time in order to reduce the risk of restenosis caused by cellular proliferation. The market effects of these new drug-eluting stents (DES) began in 2003. Today they represent 69.2 percent of the total coronary Stent market, which is expected to grow at a rate of about 4.6 percent now that the shock that surrounded the alleged DES problems has dissipated.

“Though drug-eluting stents cost three to four times as much as bare metal stents, when one examines their cost-effectiveness, the case is clear,” noted Kalorama analyst Kenneth Krul. “They remain an exciting innovation that will be a major part of cardiovascular intervention technologies over the next ten years, and it should become increasingly evident that DES use does in fact result in reduced long-term healthcare costs and improved economic outcomes.'

Kalorama Information’s report ‘Major World Markets for Stents Major World Markets for Stents and the Economics of Drug-Eluting Technology’ focuses on the market applications of current and advanced technologies in the development of coronary stents, with an emphasis on drug-eluting stents. The market analysis covers the seven major world healthcare markets (USA, France, Germany, Italy, Japan, Spain and the United Kingdom). Current and future trends, market size, projections, and company profiles are also provided.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo